- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.09. | Hemab Therapeutics appoints Keli Walbert to board of directors | 1 | Investing.com | ||
| 24.09. | Hemab Therapeutics, Inc.: Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert | 169 | GlobeNewswire (Europe) | CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment... ► Artikel lesen | |
| 24.09. | Hemab Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09. | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | 382 | GlobeNewswire (Europe) | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| 17.09. | Hemab Therapeutics, Inc.: Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding | 273 | GlobeNewswire (Europe) | Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care... ► Artikel lesen | |
| HEMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.08. | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | 1.270 | AFX News | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| 12.08. | H.C. Wainwright hebt Kursziel für Hemab Therapeutics auf 60 US-Dollar an | 2 | Investing.com Deutsch | ||
| 11.08. | Hemab Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | Biotech Stocks At 52-Week Highs - Delcath Systems +22% On Q2 Results, Alto Neuroscience, Hemab Therapeutics, Monopar Therapeutics, Nurix Therapeutics | 1.129 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| 14.07. | Hemab präsentiert Phase-2-Daten für Sutacimig und plant Phase-3-Studie | 2 | Investing.com Deutsch | ||
| 14.07. | Hemab presents phase 2 data for sutacimig, plans phase 3 trial | 1 | Investing.com | ||
| 14.07. | Hemab Therapeutics, Inc.: Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress | 1 | GlobeNewswire (USA) | ||
| 13.07. | Hemab Advances Bleeding Disorder Pipeline | 3 | Benzinga.com | ||
| 13.07. | Hemab Therapeutics stock price target raised to $52 by H.C. Wainwright on trial data | 1 | Investing.com | ||
| 12.07. | Hemab Therapeutics, Inc.: Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress | 3 | GlobeNewswire (USA) | ||
| 10.07. | Gubra A/S: Gubra collaboration partner Hemab to present preclinical results for HMB-003, a potential treatment for multiple bleeding disorders, at the ISTH 2026 Congress | 444 | GlobeNewswire (Europe) | Copenhagen, July 10, 2026: Gubra's collaboration partner Hemab will present preclinical results from the HMB-003 program on July 11, 2026, at the ISTH Congress in Paris.
The preclinical data show that... ► Artikel lesen | |
| 26.06. | Hemab Therapeutics: Positive Studiendaten und Pipeline-Erweiterung treiben Aktie an | 1 | Investing.com Deutsch | ||
| 26.06. | Hemab announces clinical updates across bleeding disorder pipeline | 2 | Investing.com | ||
| 26.06. | Hemab Therapeutics, Inc.: Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress | 1 | GlobeNewswire (USA) | ||
| 17.06. | H.C. Wainwright initiates Hemab Therapeutics stock coverage with buy rating | 3 | Investing.com |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 372,00 | +2,38 % | Cantor Fitzgerald raises Amgen stock price target on portfolio strength | ||
| REGENERON PHARMACEUTICALS | 668,50 | +1,43 % | Kampf gegen Hautkrebs: Wie Vidac Pharma, Biofrontera und Regeneron an verschiedenen Stellen ansetzen | Auf der Jahrestagung der Europäischen Akademie für Dermatologie und Venerologie in Wien standen zuletzt neue Ansätze für die großflächige Behandlung von Hautschäden im Fokus. Der Kampf gegen Hautkrebs... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 25,640 | -1,84 % | Celldex Therapeutics, Inc.: Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints | Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSUEMBARQ-CSU1 and -CSU2 met primary and all key secondary... ► Artikel lesen | |
| ARGENX | 736,00 | +1,13 % | BERNSTEIN RESEARCH stuft Argenx auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Argenx auf "Outperform" mit einem Kursziel von 986 Euro belassen. Der Flop der Phase-III-Studie mit dem Wirkstoff... ► Artikel lesen | |
| REVOLUTION MEDICINES | 170,55 | +1,58 % | Propanc Biopharma, Inc.: Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib | MELBOURNE, Australia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| INSMED | 89,76 | +0,17 % | Insmed CFO Sara Bonstein To Step Down | WASHINGTON (dpa-AFX) - Insmed Incorporated (INSM), a biopharmaceutical company, said on Monday that Sara Bonstein has decided to step down as chief financial officer. She will continue to serve... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 68,50 | -0,72 % | Piper Sandler bestätigt Rating für Oruka Therapeutics angesichts von Pipeline-Katalysatoren | ||
| KRYSTAL BIOTECH | 295,40 | +1,23 % | $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today | ||
| ULTRAGENYX | 13,900 | +1,94 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million | NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority... ► Artikel lesen | |
| SCHOLAR ROCK | 36,930 | -1,78 % | Raymond James reiterates Scholar Rock stock rating on MAA resubmission | ||
| PALVELLA THERAPEUTICS | 116,00 | 0,00 % | Palvella Therapeutics Inc.: Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer | Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished... ► Artikel lesen | |
| IMMUNOCORE | 26,000 | +0,78 % | Immunocore Holdings Q2 2026 Earnings Call Transcript | ||
| VAXCYTE | 62,50 | +7,76 % | Vaxcyte, Inc.: Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes | SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings... ► Artikel lesen | |
| RELAY THERAPEUTICS | 17,870 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| VERA THERAPEUTICS | 29,880 | +0,50 % | Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 | BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the... ► Artikel lesen |
HEMAB THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,36 % bei einem Aktienkurs von 31,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMAB THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.